【摘要】 目的探讨糖尿病周围神经病变(DPN)患者使用依帕司他与甲钴胺联合治疗的临床价值。方法选取2017年1月至2020年3月本院收治的DPN患者100例,按照随机数表法分为两组,每组50例。对照组给予甲钴胺单药治疗,实验组在对照组基础上给予依帕司他治疗,比较两组临床药效、安全性及不同治疗阶段的运动神经与感觉神经传导状况。结果实验组临床总有效率为88.0%,高于对照组的62.0%,差异具有统计学意义(P<0.05)。治疗前,两组感觉神经与运动神经的传导速度比较差异无统计学意义;治疗后,实验组感觉神经及运动神经的传导速度均高于对照组,差异具有统计学意义(P<0.05)。两组治疗期间均未出现严重不良事件。结论依帕司他与甲钴胺联合治疗DPN患者效果确切,安全性高,能明显改善患者的感觉神经与运动神经传导速度,值得临床推广应用。更多还原

【Abstract】 Objective To study the clinical value of epalasta combined with mecobalamin in patients with diabetic peripheral neuropathy(DPN).Methods 100 DPN patients in our hospital from January 2017 to March 2020 were selected and they were divided into two groups according to the random number table method, with 50 cases in each group. The control group was treated with mecobalamin monotherapy. The experimental group was treated with ipasitra based on the control group. Compare the clinical efficacy, safety and motor nerve and sensory nerve conduction status in different treatment stages between the two groups. Results The total clinical effective rate of the experimental group was 88.0%, which was higher than 62.0%of the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no significant difference in the conduction velocities of sensory nerve and motor nerve between the two groups; after treatment, the conduction velocities of sensory nerve and motor nerve in the experimental group were higher than those in the control group, and the difference was statistically significant(P<0.05). There were no serious adverse events during the treatment period in the two groups. Conclusion The combination of epalrestat and mecobalamin in the treatment of patients with DPN has a definite effect, high safety, and can significantly improve the sensory and motor nerve conduction velocity of patients, and is worthy of clinical application.更多还原